<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00347100</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_L_01051</org_study_id>
    <nct_id>NCT00347100</nct_id>
  </id_info>
  <brief_title>Insulin Glargine in Type 2 Diabetic Patients</brief_title>
  <acronym>TARGET</acronym>
  <official_title>Treatment of Early Insulinization With Glargine in Type 2 Diabetes Patients Uncontrolled on Sulfonylurea or Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary:

        -  To investigate the efficacy of insulin glargine (in terms of change in A1c from baseline
           to endpoint A1c &lt; 7%)

      Secondary:

        -  To investigate the safety of insulin glargine (in terms of hypoglycaemia, including
           symptomatic, non-symptomatic and nocturnal hypoglycaemia)

        -  To investigate whether beta cell function is preserved if this therapy is initiated
           before 2nd OAD (oral anti-diabetic drug) failure
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A1c values</measure>
    <time_frame>At baseline and 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events including hypoglycemia</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">387</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Insulin Glargine and Sulfonylurea or Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of Sulfonylurea or Metformin + a second Oral Anti Diabetic (OAD) among Glyburide, Glyclazide,Glimiperide,Glipizide or Metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Throughout study period</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyburide</intervention_name>
    <description>Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyclazide</intervention_name>
    <description>Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimiperide</intervention_name>
    <description>Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glipizide</intervention_name>
    <description>Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes patients with first OAD (Sulfonylurea [SU] or Metformin) failure

          -  Patients who are insulin naive (unless it was used for gestational diabetes or if
             insulin therapy was less than 1 week)

          -  Serum creatinine ≤ 1.5mg/dL

          -  BMI: 21-41 kg/m²

          -  7.5%&lt; A1c &lt;11%

          -  Fasting plasma glucose &gt; 7.5mmol/L

          -  On diet and exercise therapy and stable OAD treatment (SU or metformin &gt; ½ maximal
             dose)for more than 1 month prior to enrolment

          -  Women not of childbearing potential (sterilization procedure done or menopausal &gt; 2
             years), or if of childbearing potential, agree to take reliable contraceptive measures
             during the study

          -  Able and willing to monitor blood glucose

          -  Able and willing to perform 7 point blood glucose self monitoring at baseline, 12 week
             and 24 week

          -  Understand that there is a 50% chance of being randomized to the insulin treatment arm
             and is willing to self inject insulin

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Acute complication of diabetes, such as diabetic ketoacidosis and hyperosmolar coma

          -  Pregnancy, breast-feeding

          -  People who work night shifts

          -  Hypersensitivity to investigational drugs or its additives, or intolerability to
             metformin

          -  Need for use of medications prohibited by the protocol during the study for treatment
             purpose

          -  Significant diseases in cardiovascular, liver, nerve, endocrine or other systems,
             unable to complete the study or difficult to be used in study analysis

          -  Drugs or alcohol abuse

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Jolain</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>June 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Glyburide</mesh_term>
    <mesh_term>Glipizide</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

